VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 588 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2015. The put-call ratio across all filers is 2.30 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $7,536,000 | +21.9% | 306,966 | 0.0% | 0.74% | +12.9% |
| Q2 2016 | $6,182,000 | -23.8% | 306,966 | -0.6% | 0.65% | -19.4% |
| Q1 2016 | $8,118,000 | -93.0% | 308,666 | -72.8% | 0.81% | -90.6% |
| Q4 2015 | $115,530,000 | -53.0% | 1,136,554 | -17.5% | 8.56% | -36.6% |
| Q3 2015 | $245,827,000 | -18.7% | 1,378,108 | +1.3% | 13.50% | -12.2% |
| Q2 2015 | $302,291,000 | +69.5% | 1,360,752 | +51.5% | 15.37% | +39.2% |
| Q1 2015 | $178,356,000 | +40.0% | 897,976 | +0.8% | 11.04% | +22.4% |
| Q4 2014 | $127,429,000 | -2.5% | 890,426 | 0.0% | 9.02% | -6.6% |
| Q3 2014 | $130,670,000 | +20.2% | 890,426 | +3.3% | 9.66% | +7.7% |
| Q2 2014 | $108,745,000 | +8.0% | 862,236 | +24.4% | 8.97% | +10.8% |
| Q1 2014 | $100,703,000 | +23.7% | 693,381 | 0.0% | 8.09% | +16.0% |
| Q4 2013 | $81,403,000 | +15.0% | 693,381 | +2.2% | 6.98% | -7.3% |
| Q3 2013 | $70,811,000 | +112.9% | 678,719 | +75.7% | 7.53% | +84.2% |
| Q2 2013 | $33,253,000 | – | 386,300 | – | 4.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |